Zhejiang Ausun Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical formulations, specialty active pharmaceutical ingredients (APIs), and pharmaceutical intermediates in China and internationally. The company offers products for liver diseases, respiratory system diseases, cardiovascular and cerebrovascular diseases, high-end fluorine products, prostaglandins, antibacterial agents, gout, anti-tumor treatments, and nervous system disorders. It also provides customized contract research, development, and manufacturing services. In addition, the company engages in technology research and development, commissioned technology development, technology transfer, consulting, and promotion services; wholesale of organic intermediates; medical research and experimental development; market research; conference services; organization of exhibitions and displays; import and export trade of pharmaceuticals, food, cosmetics, medical devices, goods and technology, and related instruments and equipment; drug clinical trials; retail of pharmaceuticals; technical consultation and exchange; health consultation; and research and development of biochemical products. Zhejiang Ausun Pharmaceutical Co., Ltd. was incorporated in 2010 and is headquartered in Taizhou, China.
